NCT05178355View on ClinicalTrials.gov

A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

February 12, 2019

Primary Completion Date

June 21, 2019

Study Completion Date

June 21, 2019

Conditions
Hereditary Angioedema
Interventions
DRUG

KVD824

Active

DRUG

Placebo to KVD824

Placebo

Trial Locations (1)

Unknown

KalVista Investigative Site, Merthyr Tydfil

Sponsors
All Listed Sponsors
lead

KalVista Pharmaceuticals, Ltd.

INDUSTRY

NCT05178355 - A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy Volunteers | Biotech Hunter | Biotech Hunter